ClinicalTrials.gov record
Terminated Phase 3 Interventional

A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

ClinicalTrials.gov ID: NCT05348915

Public ClinicalTrials.gov record NCT05348915. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 10:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial

Study identification

NCT ID
NCT05348915
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
242 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 28, 2022
Primary completion
Nov 6, 2025
Completion
Nov 6, 2025
Last update posted
Dec 16, 2025

2022 – 2025

United States locations

U.S. sites
18
U.S. states
10
U.S. cities
10
Facility City State ZIP Site status
Strada Patient Care Center, Pediatric Hematology Mobile Alabama 36604
University of South Alabama Children's and Women's Hospital Mobile Alabama 36604
South Alabama Medical Science Foundation Mobile Alabama 36606
Arkansas Children's Hospital Little Rock Arkansas 72202
UC Irvine Medical Center Orange California 92868
UConn-Neag Comprehensive Cancer Center Farmington Connecticut 06030
University of Illinois at Chicago (UIC) Clinical Research Center Chicago Illinois 60612
University of Illinois Hospital and Health Sciences System (UI Health) Chicago Illinois 60612
Brigham And Woman's Hospital Boston Massachusetts 02115
Dana-Farber Cancer Institute IDS Pharmacy Boston Massachusetts 02215
Dana-Farber Cancer Institute Boston Massachusetts 02215
University of Michigan Hospitals - Michigan Medicine Ann Arbor Michigan 48109
Jacobi Medical Center The Bronx New York 10461
Duke University Medical Center Durham North Carolina 27705
DUMC Investigational Drug Services Pharmacy Durham North Carolina 27710
McGovern Medical School at UTHealth Houston Texas 77030
UT Health Science Center at Houston - Clinical Research Unit at Memorial Hermann Hospital Houston Texas 77030
UT Physicians Comprehensive Sickle Cell Center Houston Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05348915, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 16, 2025 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05348915 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →